IB-MECA has been shown to act as a potent and selective Adenosine A3-R agonist with Ki values of 1.1, 54 and 56 nM for Adenosine A3-R, Adenosine A1-R and Adenosine A2A-R, respectively.
More Information Supplier PageRN-1 2HCl exhibits selectivity for LSD1 over monoamine oxidase (MAO)-A and MAO-B (IC50 values are 70 nM, 0.51 and 2.79 ??M respectively, in a horseradish peroxidase-coupled assay).
More Information Supplier PageRN-1 2HCl exhibits selectivity for LSD1 over monoamine oxidase (MAO)-A and MAO-B (IC50 values are 70 nM, 0.51 and 2.79 ??M respectively, in a horseradish peroxidase-coupled assay).
More Information Supplier PageRN-1 2HCl exhibits selectivity for LSD1 over monoamine oxidase (MAO)-A and MAO-B (IC50 values are 70 nM, 0.51 and 2.79 ??M respectively, in a horseradish peroxidase-coupled assay).
More Information Supplier Pagea5IA is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme.
More Information Supplier Pagea5IA is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme.
More Information Supplier Pagea5IA is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme.
More Information Supplier PageAPD668 is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119 respectively.
More Information Supplier PageIB-MECA has been shown to act as a potent and selective Adenosine A3-R agonist with Ki values of 1.1, 54 and 56 nM for Adenosine A3-R, Adenosine A1-R and Adenosine A2A-R, respectively.
More Information Supplier PageLGD-4033 is an investigational selective androgen receptor modulator for treatment of conditions such as muscle wasting and osteoporosis, currently under development by Ligand Pharmaceuticals.
More Information Supplier Page
